Preservation of Immune Repertoire by Selective Depletion of Haploidentical Grafts

Guinan, Eva C.; Luzmik, Leo; Handgretinger, Rupert; Woolfrey, Ann E.

doi:10.1016/j.bbmt.2009.11.015

Cited by 2 publications

(1 citation statement)

References 29 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, mycophenolate mofetil was used as post-transplantation immunosuppression when the T cell content in the graft was Ն5 ϫ 10 4 CD3 ϩ cells/kg [170]. Selective depletion of or induction of anergy in the alloreactive T lymphocytes, as well as adoptive transfer of pathogen-specific T cell populations, has been developed to offer refined ways to target infections, without increasing the risk of GvHD [171][172][173][174].…”

Section: On the Contrary ␥␦ T Cells And Alloreactive Nk Cells Via Tmentioning

confidence: 99%

At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias

Norell

Moretta

Silva‐Santos

et al. 2013

Journal of Leukocyte Biology

View full text Add to dashboard Cite

NK cells and γδ T lymphocytes display potent cytolytic activity against leukemias and CMV-infected cells and are thus, promising immune effector cells in the context of allo-HSCT. NK cells express HLA class I-specific inhibitory receptors and preferentially kill HLA class I(low) tumors or virus-infected cells. Killing occurs upon engagement of activating NKRs with ligands that are up-regulated on tumors and infected cells. A similar activating receptor/ligand interaction strategy is used by γδ T cells, which in addition, use their TCRs for recognition of phosphorylated antigens and still largely undefined ligands on tumor cells. In the haploidentical allo-HSCT setting, alloreactive NK cells, derived from donor HSCs, can exert potent antileukemia activity and kill residual patient DCs and T cells, thus preventing GvHD and graft rejection. However, generation of KIR(+) alloreactive NK cells from HSCs requires many weeks, during which leukemia relapses, and life-threatening infections may occur. Importantly, mature NK cells and γδ T cells can control certain infectious agents efficiently, in particular, limit CMV reactivation, and infusion of such donor cells at the time of HSCT has been implemented. Development of novel, cell-based immunotherapies, allowing improved trafficking and better targeting, will endow NK cells and γδ T lymphocytes with enhanced anti-tumor activity, also making them key reagents for therapies against solid tumors. The clinical aspects of using NK cells and γδ T lymphocytes against hematological malignancies, including the allo-HSCT context, are reviewed in the related side-by-side paper by Locatelli and colleagues [1].

show abstract

Section: On the Contrary ␥␦ T Cells And Alloreactive Nk Cells Via Tmentioning

confidence: 99%

At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias

Norell

Moretta

Silva‐Santos

et al. 2013

Journal of Leukocyte Biology

View full text Add to dashboard Cite

show abstract

Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies

Petrović¹,

Hale²

2011

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Preservation of Immune Repertoire by Selective Depletion of Haploidentical Grafts

Cited by 2 publications

References 29 publications

At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias

At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias

Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies

Contact Info

Product

Resources

About